• Results for the Second Quarter 2017

    Currency neutral growth of own products was 4.7 % and was negatively impacted by delayed flow probe deliveries amounting to MNOK 5.5. Currency neutral growth of own products was 10.7 % for the 1st half.…

    Read more
  • Results for the Fourth Quarter 2016

    Currency neutral sales of own products decreased with 3 MNOK or 5.7 % due in part to a back order situation on TTFM flow probes. Currency neutral sales of own products increased with 9.5 %…

    Read more
  • Results for the Third Quarter 2016

    Sales in the 3rd quarter ended at MNOK 67.9 (MNOK 61.6), a 10.2 % increase. USA had a strong quarter with an 18.5% growth in sales. In Asia sales increased with 83.6 % while in…

    Read more
  • Results for the First Quarter 2016

    Sales for the quarter ended at MNOK 65.5 which is a 13.1 % sales growth for the quarter. Sales of own products increased with 28.8 % to MNOK 49.1 and US sales up 42.8 %…

    Read more
  • Medistim Delivers Best Quarter Ever

    Medistim delivers its best quarter ever and sales ended at MNOK 66.1 (MNOK 52.2), a growth of 26.6 %. Sales for 2014 ended at MNOK 214.8 (MNOK 191.0), a growth of 12.5 %. The atrong…

    Read more
  • Results for the Third Quarter 2014

    Sales for the quarter ended at MNOK 52.0 (MNOK 44.3), a growth of 17 %. Sales as of September ended at MNOK 148.7 (MNOK 138.8), a growth of 7.1 %. • Continued strong growth in…

    Read more
  • MiraQ™ Cardiac Launched in the European Market

    (Oslo, 13 October 2014) Medistim ASA (OSE: MEDI), a Norwegian company that develops and commercializes medical equipment for use in cardiac, vascular and transplant surgery, announces that they launch its new product MiraQ Cardiac in…

    Read more
  • Results for the Second Quarter and First Half 2014

    Sales ended at MNOK 47.9 for the quarter (MNOK 49.0). Sales for the 1st half increased by 2.3 % and ended at MNOK 96.7 (MNOK 94.5). (more…)

    Read more
  • Results for the First Quarter 2014

    Sales for the quarter ended at MNOK 48.9 (MNOK 45.5) and operating profit (EBIT) ended at MNOK 7.2 (MNOK 7.3). It was a strong development in imaging sales with a 67 % increase in capital sales.…

    Read more
  • Record Sales in Fourth Quarter 2013

    Medistim delivers record sales for a quarter with MNOK 52.2 (MNOK 49.7). Sales for 2013 ended at MNOK 191 (MNOK 183.8), which is a 3.9 % growth. Operating profit (EBIT) for the quarter ended at…

    Read more